Adaptation of human iPSC-derived cardiomyocytes to tyrosine kinase inhibitors reduces acute cardiotoxicity via metabolic reprogramming
H. Wang, R. P. Sheehan, A. C. Palmer, R. A. Everley, S. A. Boswell, N. Ron-Harel, A. E. Ringel, K. M. Holton, C. A. Jacobson, A. R. Erickson, L. Maliszewski, M. C. Haigis, P. K. Sorger
Cell Systems · May 1, 2019Peer-reviewedPharmacology & Toxicology